Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eastwood Bio-Medical CanadaTSXV:EBM -1.04%25 Cyclically Adjusted PS Ratio is 191.00 as of Aug. 27, 2026, which is 218% above its 10-year median of 60.00. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.52 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 525 Biotechnology companies, Eastwood Bio-Medical Canada ranks worse than 96.19% on this metric.
The historical rank and industry rank for Eastwood Bio-Medical Canada's Cyclically Adjusted PS Ratio or its related term are showing as below:
TSXV:EBM'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 22.5 Med: 60 Max: 193
Current: 137.92
During the past years, Eastwood Bio-Medical Canada's highest Cyclically Adjusted PS Ratio was 193.00. The lowest was 22.50. And the median was 60.00.
TSXV:EBM's Cyclically Adjusted PS Ratio is ranked worse than 96.19% of 525
companies
in the Biotechnology industry
Industry Median: 6.06
vs TSXV:EBM: 137.92
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Eastwood Bio-Medical Canada's adjusted revenue per share data for the three months ended in Apr. 2026 was C$0.002. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$0.01 for the trailing ten years ended in Apr. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Eastwood Bio-Medical Canada (TSXV:EBM) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Eastwood Bio-Medical Canada Cyclically Adjusted PS Ratio Related Terms
Eastwood Bio-Medical Canada Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eastwood Bio-Medical Canada Cyclically Adjusted PS Ratio Chart
TSXV:EBM vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Eastwood Bio-Medical Canada's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eastwood Bio-Medical Canada Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Eastwood Bio-Medical Canada's Cyclically Adjusted PS Ratio falls into.
Eastwood Bio-Medical Canada Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 191.00 mean?
Eastwood Bio-Medical Canada (TSXV:EBM) has a Cyclically Adjusted PS Ratio of 191.00 as of Aug. 27, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eastwood Bio-Medical Canada and its competitors. This is 218% above median its historical median of 60.00. Over the past decade, Eastwood Bio-Medical Canada's Cyclically Adjusted PS Ratio has ranged from 22.50 to 193.00. According to the industry distribution chart, Eastwood Bio-Medical Canada ranks #505 out of 525 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Eastwood Bio-Medical Canada's Cyclically Adjusted PS Ratio too high?
Eastwood Bio-Medical Canada's current Cyclically Adjusted PS Ratio of 191.00 is 218% above median its 10-year median of 60.00. Over the past 10 years, this metric has ranged from a low of 22.50 to a high of 193.00. The Biotechnology industry median Cyclically Adjusted PS Ratio is 6.06. Eastwood Bio-Medical Canada's value of 191.00 is 3051.8% above this industry median. Based on the distribution chart, Eastwood Bio-Medical Canada ranks #505 out of 525 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eastwood Bio-Medical Canada ranks #505 out of 525 companies for Cyclically Adjusted PS Ratio. This places Eastwood Bio-Medical Canada in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 6.06. Eastwood Bio-Medical Canada's value of 191.00 is 3051.8% above this benchmark. Historically, Eastwood Bio-Medical Canada's own Cyclically Adjusted PS Ratio has ranged from 22.50 to 193.00 over the past decade. While the company's 10-year median is 60.00 vs. the industry median of 6.06, Eastwood Bio-Medical Canada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 6.06, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eastwood Bio-Medical Canada's current Cyclically Adjusted PS Ratio of 191.00 is 3051.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eastwood Bio-Medical Canada and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 6.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eastwood Bio-Medical Canada's current Cyclically Adjusted PS Ratio is 191.00, which is 218% above median its own 10-year median of 60.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.52, compared to a current price of C$1.91 — trading 267.3% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 191.00, which is 218% above median its 10-year median of 60.00 and 3051.8% above the Biotechnology industry median of 6.06. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current Cyclically Adjusted PS Ratio is 191.00 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued.
The current stock price of C$1.91 is trading 267.3% above its estimated GF Value™ of C$0.52.
GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.
Key valuation signals for TSXV:EBM:
Cyclically Adjusted PS Ratio: 191.00 (218% above median its 10-year median of 60.00)
GF Value™: C$0.52 vs. price of C$1.91 (267.3% above fair value)
Industry Position: 3051.8% above the Biotechnology median (#505 of 525)
No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score
Get the complete analysis for TSXV:EBM
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EBM has been successfully added to your 
